newsfilter
← Latest News
GlobeNewswire·

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

Successfully dosed first patient in TCR-T Library Phase 1/2 trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications Will present preclinical data today at the ASGCT 25th Annual Meeting highlighting the potential of mbIL-15 as